Gyre Therapeutics (GYRE) FCF Payout Ratio (2023)

Gyre Therapeutics (GYRE) reported FCF Payout Ratio of 0.27 for Q3 2023, down 84.29% quarter-over-quarter from 1.7 in Q2 2023.

Gyre Therapeutics (GYRE) FCF Payout Ratio (2023) Analysis & Trends

Gyre Therapeutics (GYRE) has 1 years of FCF Payout Ratio data on file, last reported at 0.27 in Q3 2023.

FCF Payout Ratio for Q3 2023 came in at 0.27, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was 0.22 (changed N/A YoY), and the FY2022 annual result was 7.91, changed N/A from the prior year.
FCF Payout Ratio declined to 0.27 in Q3 2023 per GYRE's latest filing, from 1.7 in the prior quarter.
Over five years, FCF Payout Ratio peaked at 1.7 in Q2 2023 and troughed at 0.27 in Q3 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Gyre Therapeutics	554.75 Mn	540.62 Mn	8.38 Mn	-

Historic Data

Download Data

Date	Value
Sep 30, 2023	0.27
Jun 30, 2023	1.70
Mar 31, 2023	0.89